Pacific Biosciences of California, Inc. Announces Proposed Public Offering of Common Stock

Rhea-AI Summary

Pacific Biosciences (PACB) announced a public offering of $75 million in common stock, with an option for underwriters to purchase an additional $11.25 million. The proceeds will be used for new product launches, research and development, and expanding commercial infrastructure. The offering is subject to market conditions and may not be completed as anticipated. The company has filed a registration statement with the SEC, effective July 14, 2020, and a preliminary prospectus will be available for investors.

Positive

• Intended use of proceeds for product launches and R&D could drive future growth.
• Possibility of acquiring complementary businesses or technologies.

Negative

• Equity dilution risk for existing shareholders due to new stock issuance.
• Market conditions may affect the completion and terms of the offering.

MENLO PARK, Calif., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq: PACB) today announced that it intends to offer and sell $75.0 million of shares of its common stock in an underwritten public offering.  Pacific Biosciences also intends to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.  The offering is subject to market and other conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Morgan Stanley & Co. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Cantor Fitzgerald & Co. is also acting as a book-running manager for the offering.

Pacific Biosciences intends to use the net proceeds from the offering for (i) additional product launches and research and development, (ii) commercial infrastructure expansion and (iii) general corporate purposes.  Pacific Biosciences may also use a portion of the net proceeds from the offering to acquire or invest in complementary businesses, technologies, product candidates or other intellectual property, although it has no present commitments or agreements to do so.

A shelf registration statement relating to the shares of common stock was previously filed with the Securities and Exchange Commission (the “SEC”) and declared effective on July 14, 2020.  A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website. Copies of the preliminary prospectus supplement (when available) and accompanying prospectus may be obtained from Morgan Stanley & Co. LLC, Prospectus Department, 180 Varick Street, Second Floor, New York, NY 10014 or Cowen and Company, LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY, 11717, Attn: Prospectus Department, by email at PostSaleManualRequests@broadridge.com or by telephone at (833) 297-2926.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction. Any offer, if at all, will be made only by means of the prospectus supplement and accompanying prospectus forming a part of the effective registration statement.

About Pacific Biosciences

Pacific Biosciences of California, Inc. (Nasdaq: PACB), is empowering life scientists with highly accurate long-read sequencing. The company’s innovative instruments are based on Single Molecule, Real-Time (SMRT®) Sequencing technology, which delivers a comprehensive view of genomes, transcriptomes, and epigenomes, enabling access to the full spectrum of genetic variation in any organism. Cited in thousands of peer-reviewed publications, PacBio® sequencing systems are in use by scientists around the world to drive discovery in human biomedical research, plant and animal sciences, and microbiology.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially, including, but not limited to, whether or not Pacific Biosciences will be able to raise capital through the sale of shares of common stock or consummate the offering, the final terms of the offering, the satisfaction of customary closing conditions, prevailing market conditions, the anticipated use of the proceeds of the offering which could change as a result of market conditions or for other reasons, and the impact of general economic, industry or political conditions in the United States or internationally.  Additional risks and uncertainties relating to the offering, Pacific Biosciences and its business can be found under the heading “Risk Factors” in Pacific Biosciences’ most recent periodic, quarterly and annual reports filed with the SEC and in the preliminary prospectus supplement and accompanying prospectus relating to the offering to be filed with the SEC.  Pacific Biosciences assumes no duty or obligation to update or revise any forward-looking statements for any reason.

Contact:
Investors: Trevin Rard
650.521.8450
ir@pacificbiosciences.com

FAQ

What is the size of Pacific Biosciences' public offering?

Pacific Biosciences is offering $75 million in common stock, with an additional $11.25 million option for underwriters.

What will the proceeds from PACB's stock offering be used for?

The proceeds will be used for product launches, research and development, and expanding commercial infrastructure.

Who are the underwriters for the PACB offering?

Morgan Stanley, Cowen, and Cantor Fitzgerald are acting as underwriters for the offering.

When was PACB's registration statement declared effective?

The registration statement was declared effective on July 14, 2020.

What are the risks associated with PACB's stock offering?

Risks include potential equity dilution for existing shareholders and the uncertainty of market conditions affecting the offering's completion.